| __timestamp | ADMA Biologics, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 9517014 | 55430000 |
| Thursday, January 1, 2015 | 7015946 | 65510000 |
| Friday, January 1, 2016 | 7688238 | 71160000 |
| Sunday, January 1, 2017 | 6229587 | 70644000 |
| Monday, January 1, 2018 | 3926120 | 70418000 |
| Tuesday, January 1, 2019 | 2343848 | 63238000 |
| Wednesday, January 1, 2020 | 5907013 | 59777000 |
| Friday, January 1, 2021 | 3646060 | 60152000 |
| Saturday, January 1, 2022 | 3613764 | 54540000 |
| Sunday, January 1, 2023 | 3300000 | 52243000 |
| Monday, January 1, 2024 | 64536000 |
Unleashing insights
In the competitive landscape of biopharmaceuticals, strategic investment in research and development (R&D) is crucial for innovation and growth. Over the past decade, ADMA Biologics, Inc. and Taro Pharmaceutical Industries Ltd. have demonstrated contrasting approaches to R&D spending. From 2014 to 2023, Taro consistently allocated a significant portion of its resources to R&D, peaking in 2016 with a 71 million USD investment. This commitment underscores Taro's focus on maintaining a robust pipeline of pharmaceutical innovations.
Conversely, ADMA Biologics exhibited a more fluctuating R&D expenditure pattern, with a notable high in 2014, investing approximately 9.5 million USD, followed by a gradual decline. By 2023, ADMA's R&D spending had decreased by over 65%, reflecting a strategic shift or potential resource constraints. This divergence in R&D strategies highlights the varied paths companies take in the pursuit of pharmaceutical advancements.
Comparing Innovation Spending: Merck & Co., Inc. and ADMA Biologics, Inc.
R&D Spending Showdown: Amgen Inc. vs Taro Pharmaceutical Industries Ltd.
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and ADMA Biologics, Inc.
R&D Insights: How Bio-Techne Corporation and ADMA Biologics, Inc. Allocate Funds
Research and Development Expenses Breakdown: Ionis Pharmaceuticals, Inc. vs ADMA Biologics, Inc.
Research and Development Investment: Ionis Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
R&D Spending Showdown: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
Research and Development: Comparing Key Metrics for TG Therapeutics, Inc. and ADMA Biologics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for ADMA Biologics, Inc. and Iovance Biotherapeutics, Inc.
Research and Development: Comparing Key Metrics for ADMA Biologics, Inc. and Viridian Therapeutics, Inc.
R&D Insights: How CymaBay Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd. Allocate Funds
R&D Insights: How Veracyte, Inc. and Taro Pharmaceutical Industries Ltd. Allocate Funds